Tags

Type your tag names separated by a space and hit enter

The drug treatment of Parkinson's disease.
Aust Fam Physician. 1984 May; 13(5 Suppl):6-8, 11.AF

Abstract

The drug treatment of Parkinson's disease should be tailored to the age of the patient, coexistence of dementia or postural hypotension, duration of the disease process and the emergence of side effects. In the early stages of the disease when disability is minimal, amantadine or anti-cholinergic drugs may suffice. As the patient's lifestyle becomes hampered, levodopa in combination with carbidopa or benserazide is introduced. Mild dopa induced dyskinesia can be ignored but when it is troublesome the dose of levodopa should be reduced. Fluctuations are minimised by giving small doses of levodopa frequently throughout the day or by adding bromocriptine to the drug regimen. Postural symptoms often respond to fludrocortisone and elevation of the head of the bed. In elderly or demented patients anticholinergic drugs and amantadine should be avoided. In these patients small doses of levodopa alone may be preferable to the combined preparations. More effective drugs with fewer side effects are likely to emerge with future successful research into the different types of dopamine receptors and other possible transmitters.

Authors

No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

6497767

Citation

Morris, J G.. "The Drug Treatment of Parkinson's Disease." Australian Family Physician, vol. 13, no. 5 Suppl, 1984, pp. 6-8, 11.
Morris JG. The drug treatment of Parkinson's disease. Aust Fam Physician. 1984;13(5 Suppl):6-8, 11.
Morris, J. G. (1984). The drug treatment of Parkinson's disease. Australian Family Physician, 13(5 Suppl), 6-8, 11.
Morris JG. The Drug Treatment of Parkinson's Disease. Aust Fam Physician. 1984;13(5 Suppl):6-8, 11. PubMed PMID: 6497767.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The drug treatment of Parkinson's disease. A1 - Morris,J G, PY - 1984/5/1/pubmed PY - 1984/5/1/medline PY - 1984/5/1/entrez SP - 6-8, 11 JF - Australian family physician JO - Aust Fam Physician VL - 13 IS - 5 Suppl N2 - The drug treatment of Parkinson's disease should be tailored to the age of the patient, coexistence of dementia or postural hypotension, duration of the disease process and the emergence of side effects. In the early stages of the disease when disability is minimal, amantadine or anti-cholinergic drugs may suffice. As the patient's lifestyle becomes hampered, levodopa in combination with carbidopa or benserazide is introduced. Mild dopa induced dyskinesia can be ignored but when it is troublesome the dose of levodopa should be reduced. Fluctuations are minimised by giving small doses of levodopa frequently throughout the day or by adding bromocriptine to the drug regimen. Postural symptoms often respond to fludrocortisone and elevation of the head of the bed. In elderly or demented patients anticholinergic drugs and amantadine should be avoided. In these patients small doses of levodopa alone may be preferable to the combined preparations. More effective drugs with fewer side effects are likely to emerge with future successful research into the different types of dopamine receptors and other possible transmitters. SN - 0300-8495 UR - https://www.unboundmedicine.com/medline/citation/6497767/The_drug_treatment_of_Parkinson's_disease_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -